PMS-ERLOTINIB DIN 02454394
Status: Marketed
Holder: PHARMASCIENCE INC
Molecule: ERLOTINIB (ERLOTINIB HYDROCHLORIDE)
Available to quote
Health Canada record
| Active ingredient(s) | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 150 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EB02 ERLOTINIB |
| Original market date | 28-Jul-2016 |
| Current status date | 28-Jul-2016 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pharmascience Inc. — licence 100241, currently licensed, last inspection rating C (2025-03-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ERLOTINIB (ERLOTINIB HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02461889 | APO-ERLOTINIB | APOTEX INC | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 150 MG | Marketed |
| 02461862 | APO-ERLOTINIB | APOTEX INC | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 25 MG | Marketed |
| 02461870 | APO-ERLOTINIB | APOTEX INC | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 100 MG | Marketed |
| 02377691 | TEVA-ERLOTINIB | TEVA CANADA LIMITED | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 25 MG | Marketed |
| 02377705 | TEVA-ERLOTINIB | TEVA CANADA LIMITED | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 100 MG | Marketed |
| 02377713 | TEVA-ERLOTINIB | TEVA CANADA LIMITED | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 150 MG | Marketed |
| 02483912 | NAT-ERLOTINIB | NATCO PHARMA (CANADA) INC | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 25 MG | Dormant |
| 02483939 | NAT-ERLOTINIB | NATCO PHARMA (CANADA) INC | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 150 MG | Dormant |
| 02483920 | NAT-ERLOTINIB | NATCO PHARMA (CANADA) INC | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 100 MG | Dormant |
| 02454386 | PMS-ERLOTINIB | PHARMASCIENCE INC | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 100 MG | Dormant |
| 02269007 | TARCEVA | HOFFMANN-LA ROCHE LIMITED | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 25 MG | Cancelled Post Market |
| 02269023 | TARCEVA | HOFFMANN-LA ROCHE LIMITED | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 150 MG | Cancelled Post Market |
| 02269015 | TARCEVA | HOFFMANN-LA ROCHE LIMITED | Tablet | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 100 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18042 | 2016-05-02 | Abbreviated New Drug Submission (ANDS) |